LIVING HOPE: Part 2 on Clinical Trials (and what to expect)

In this second part of the 'Living Hope' series on clinical trials, host Roberta continues her conversation with Megan Lyles, a clinical research professional, diving deep into the realities of participating in cancer clinical trials—particularly for pancreatic cancer. The discussion centers on the informed consent process, which is detailed, lengthy (typically 20–25 pages), and designed to be at an eighth-grade reading level despite often being complex. Megan emphasizes that patients should take their time reviewing the document, ask questions during doctor visits, and discuss it with family or trusted advisors. She highlights that clinical trials are not just a last resort but can be a proactive, hopeful step, especially when patients are earlier in their treatment journey. The episode also explores the robust safety infrastructure behind trials, including Institutional Review Boards (IRBs) and Data Monitoring Committees (DMCs), which ensure patient safety through independent oversight and real-time data review. Patients retain full control over their participation and can withdraw at any time without affecting their standard care. Megan shares that many patients express regret not knowing about trials sooner and value the extra attention and sense of purpose they receive during trials. The episode concludes with a strong call to action: patients should leverage advocacy groups like Trican and Blood Cancer United (formerly LLS) to find trials, as many local physicians may not recommend them due to systemic barriers or lack of familiarity.